All posts by: Michael Zand

Theraclion Reports Significant Milestone Achievement with Its Immunotherapy Breast Cancer Strategy – Business Wire (press release)

Theraclion Reports Significant Milestone Achievement with Its Immunotherapy Breast Cancer StrategyBusiness Wire (press release)MALAKOFF, France–(BUSINESS WIRE)–THERACLION (Paris:ALTHE) (Euronext Growth, FR0010120402 – ALTHE), a company specialized in… Continue reading

Dopo le forbici, il coltellino svizzero per taglia-incolla del Dna – ANSA.it

The CRISPR Journal debuts content from Francisco Mojica, Jacob Sherkow, Rodolphe Barrangou – EurekAlert (press release)

EurekAlert (press release)The CRISPR Journal debuts content from Francisco Mojica, Jacob Sherkow, Rodolphe BarrangouEurekAlert (press release)8, 2018 — In a colorful and first-person look at the discovery of CRISPR short DNA repeats that spawned the g… Continue reading

Neoadjuvant Immunotherapy Being Investigated in Early-Stage NSCLC – OncLive

OncLiveNeoadjuvant Immunotherapy Being Investigated in Early-Stage NSCLCOncLiveOncLive: What type of data do we have thus far exploring immunotherapy in early-stage lung cancer? Kim: So far, there have been a couple of phase II trials that have looked … Continue reading

Editas Medicine Reports on Recent Progress and Announces “EM22” Five-year Goals at JP Morgan Healthcare … – Markets Insider

Nasdaq FortuneEditas Medicine Reports on Recent Progress and Announces “EM22” Five-year Goals at JP Morgan Healthcare …Markets InsiderAs a leading genome editing company, Editas Medicine is focused on translating the power and potential of the … Continue reading

Beta blockers may boost immunotherapy, help melanoma patients live longer – EurekAlert (press release)

Beta blockers may boost immunotherapy, help melanoma patients live longerEurekAlert (press release)HERSHEY, Pa. — A common, inexpensive drug that is used to prevent heart attacks and lower blood pressure may also help melanoma patients live longer, ac… Continue reading

Uh-oh! CRISPR gene-editing stocks may be worthless – USA TODAY

USA TODAYUh-oh! CRISPR gene-editing stocks may be worthlessUSA TODAYThe big-ticket item is that this journal article reported that most humans probably have pre-existing immune defenses against the "cutting element" in CRISPR known as Cas9. … Continue reading